Literature DB >> 30182378

HUS1 checkpoint clamp component (HUS1) is a potential tumor suppressor in primary hepatocellular carcinoma.

Zi-Qi Zhou1,2, Jing-Jing Zhao1,2, Chang-Long Chen1,2, Yuan Liu1,2, Jian-Xiong Zeng1,2, Zheng-Rong Wu3, Yan Tang1,2, Qian Zhu1,2, De-Sheng Weng1,2, Jian-Chuan Xia1,2.   

Abstract

The HUS1 checkpoint clamp component (HUS1), which is a member of an evolutionarily conserved, genotoxin-activated checkpoint complex (Rad9-Rad1-Hus1 [9-1-1] complex), is involved in cell cycle arrest and DNA repair in response to DNA damage. We conducted this study to investigate the biological significances of HUS1 expression in hepatocellular carcinoma (HCC) development. The mRNA and protein expression levels of HUS1 were determined using Real-time PCR and Western blot, respectively. One hundered and twenty four paraffin sections from HCC tissues were analyzed by immunohistochemistry to assess the association between HUS1 expression and clinicopathological characteristics of patients. The Kaplan-Meier method was performed to calculate the OS and RFS curves. Cell proliferation and colony formation assays, cell migration and invasion assays and cell cycle assays were used to determine the suppressor role of HUS1 in vitro. A mouse model was used to determine the effect of HUS1 on tumorigenesis. The expression of HUS1 was significantly decreased in HCC cell lines and tissues, and low HUS1 expression was associated with poor prognosis of HCC patients. Upregulation of HUS1 expression inhibited the cell proliferation, colony formation, migration, and invasion, as well as arrested cell cycle at G0/G1 in HCC cells in vitro. Moreover, sufficient HUS1 expression inhibited the tumor growth in nude mice. Our study revealed for the first time that HUS1 is a potential tumor suppressor that might produce an antitumor effect in human HCC. Furthermore, HUS1 may serve as a prognostic indicator and could be used for therapeutic application in HCC patients.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  HUS1; Hepatocellular carcinoma (HCC); cell cycle; cell proliferation; tumor suppressor

Mesh:

Substances:

Year:  2018        PMID: 30182378     DOI: 10.1002/mc.22908

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  3 in total

1.  HUS1 as a Potential Therapeutic Target in Urothelial Cancer.

Authors:  Andrea Katharina Lindner; Tobias Furlan; Jacob J Orme; Gennadi Tulchiner; Nina Staudacher; David D'Andrea; Zoran Culig; Renate Pichler
Journal:  J Clin Med       Date:  2022-04-15       Impact factor: 4.964

2.  In vivo miRNA knockout screening identifies miR-190b as a novel tumor suppressor.

Authors:  Hui Hong; Shun Yao; Yuanyuan Zhang; Yi Ye; Cheng Li; Liang Hu; Yihua Sun; Hsin-Yi Huang; Hongbin Ji
Journal:  PLoS Genet       Date:  2020-11-02       Impact factor: 5.917

3.  Prognosis and modulation mechanisms of COMMD6 in human tumours based on expression profiling and comprehensive bioinformatics analysis.

Authors:  Mi Yang; Weiqiang Huang; Yaling Sun; Huazhen Liang; Min Chen; Xixi Wu; Xiaoqing Wang; Longshan Zhang; Xiaoya Cheng; Yao Fan; Hua Pan; Longhua Chen; Jian Guan
Journal:  Br J Cancer       Date:  2019-09-16       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.